ERNA vs OKTA · P/E 0.0, rev $582.0K vs P/E 84, rev $2.61B
Eterna Therapeutics Inc (ERNA) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Eterna Therapeutics Inc (ERNA) is a biotechnology company listed on NASDAQ.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported ERNA revenue for 2024-12-31 was $582.0K. Net income was -$44.5M. Revenue was up 755.9% from 2023-12-31 to 2024-12-31. ERNA currently screens at market cap $6.9M and trailing P/E 0.0.
Latest reported OKTA revenue for 2025-01-31 was $2.61B. Net income was $28.0M. Revenue was up 15.3% from 2024-01-31 to 2025-01-31. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
ERNA currently screens at market cap $6.9M and trailing P/E 0.0. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the ERNA and OKTA stock pages for the full models.
Not investment advice.